Fapon Biotech in strategic partnership with Roche Diagnostics

Fapon Biotech Inc. (Fapon Biotech) officially went into strategic partnership with Roche Diagnostics China (Roche Diagnostics) at the 5thChina International Import Expo (CIIE) on 5 November 2022. There will be close cooperation between Fapon Biotech and Roche Diagnostics in raw material products and services, and molecular diagnostics. Based on pooled resources and combined strengths, Fapon Biotech and Roche Diagnostics will together develop and improve one-stop solutions to meet local needs, and speed up R&D and translation of research results, promoting constant innovation in the China IVD industry.

Fapon Biotech and Roche Diagnostics will collaborate on expanding lines of business along the industrial chain to meet local needs. With new business models, the two companies will jointly provide raw material solutions of higher quality and with increased diversity. The strategic partnership will surely help satisfy the changeable and customized market needs, and therefore stimulate constant innovation in in vitro diagnostics.

Cooperative Efforts of Innovation

With extensive resources and R&D experience gained worldwide over the past two decades, Fapon Biotech is now a key player in the China IVD market—a leading upstream company in the China life sciences industry and in the global IVD industry. With our platform-based ecosystem, we are one of the pioneers to offer IVD solutions combining raw materials, reagents and instruments. Our raw materials, in various categories more than others, have the largest market shares in China. We are also one of the few Chinese companies to penetrate high-end IVD markets in Europe, America and Japan. Our sales networks are present in 61 countries and regions across Europe, Americas, Asia, Oceania and Africa, connecting more than 1,500 business partners.

“At Fapon Biotech, we have been dedicated to IVD since we started two decades ago”, said Ben HE, the President of Fapon Biotech, at the signing ceremony, “we have striven to provide products and services of higher quality, and collaborated with business partners on ecosystem development through continuous innovation in technologies and platforms. The combined strengths from the strategic partnership with Roche Diagnostics make it possible to launch innovative and more accessible solutions of precision medicine. We wish to help build a better world.”

A New Chapter of Collaboration

As a globally leading IVD company, Roche Diagnostics has been dedicated to introduction of innovative products and services into China since it entered the China market in 2000. Meanwhile, it has explored and developed win-win business models with outstanding Chinese companies for solutions to meet local needs. Its efforts have encouraged innovation in the local industry, and contributed continuously to a healthy China.

Jianzhong YUAN, Vice President of Roche Diagnostics China, expressed confidence in and expectation of the strategic partnership at the signing ceremony. “At Roche Diagnostics, for over 20 years we have been operating in China and for China. We have cooperated with excellent Chinese companies in precision medicine. Today at the open collaborative platform, CIIE, we are delighted to strike strategic partnership with Fapon Biotech, a leading upstream company in the China IVD industry, in building an innovative ecosystem. Jointly, we are now at the starting point of introducing innovative solutions and technologies of precision medicine into the China market. May we write a new chapter on better satisfaction of local customer needs and improvement of health levels in China.”

About Roche Diagnositics

Roche Diagnostics is committed to developing and providing innovative and cost-effective diagnostic systems and solutions for early detection, prevention, diagnosis and monitoring of diseases so as to help healthcare professionals increase treatment outcome, improve people’s life and reduce medical costs.

Roche is the one of the global innovative leaders with combined strengths of diagnostics and pharmaceuticals under one roof. This unique combination enables Roche to leverage breakthrough knowledge to develop innovative products, detect and monitor diseases and guide the medical decisions.

Roche Diagnostics (Shanghai) Co., Ltd., solely foreign-funded, was established in August 2000 in the Waigaoqiao Free Trade Zone, getting into the market of China’s mainland.

With the growing business and company scale, Roche Diagnostics China has become one of the market leaders in vitro diagnostics in China. There are over 3,000 employees as of 2021. The headquarters is in Shanghai, with branches in Beijing, Guangzhou, Chengdu, Nanjing, Wuhan, Xi’an, Hangzhou, Jinan and Urumqi.

The sales and service networks across China supply excellent products and services, enjoying high reputation in the market. In the future, Roche Diagnostics will also join hands with all parties to actively participate in the construction of medical innovation projects, with a view to bringing more cutting-edge in vitro diagnostic solutions to China for the benefit of Chinese patients and the development of China's medical industry.